Lisata Therapeutics Q3 net loss narrows to $4.2 mln
I'm PortAI, I can summarize articles.
Lisata Therapeutics reported a Q3 net loss of $4.2 million, down from $4.9 million year-over-year. Operating expenses decreased by 17.3% to $4.4 million. The company projects its cash reserves will fund operations into Q1 2027, with no debt. Analysts maintain a "buy" rating, with a median 12-month price target of $15.00, representing an 84.4% upside from its recent closing price of $2.34.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments